Belite Bio, Inc
Price Action
Technical Summary
EMERGING TRENDBelite Bio, Inc is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 52), indicating performance broadly in line with the market. Earnings contraction of 125% provides fundamental context to the price action. Investors should exercise caution due to high volatility (53% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $145.30 | +6.00% | ABOVE |
| 50 SMA | $147.99 | +4.08% | ABOVE |
| 100 SMA | $158.99 | -3.12% | BELOW |
| 150 SMA | $158.86 | -3.05% | BELOW |
| 200 SMA | $142.50 | +8.09% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BLTE in an uptrend right now?
BLTE has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is BLTE overbought or oversold?
BLTE's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.
Is BLTE outperforming the market?
BLTE has a Relative Strength (RS) Rating of 52 out of 99. BLTE is performing about average compared to the market.
Where is BLTE in its 52-week range?
BLTE is trading at $154.02, which is 77% of its 52-week high ($200.00) and 68% above its 52-week low ($57.99).
How volatile is BLTE?
BLTE has a Beta of 0.93 and 52-week volatility of 53%. It's less volatile than the S&P 500 - generally more stable.